ストックスクリーナーアプリを入手
0.661
5.93%
0.037
アフターアワーズ：
.66
-0.001
-0.15%
Calcimedica Inc (CALC) 最新ニュース
Oppenheimer Adjusts CalciMedica Price Target to $10 From $20, Maintains Outperform Rating - marketscreener.com
CalciMedica price target lowered to $10 from $20 at Oppenheimer - TipRanks
CALC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Calcimedica Inc files for mixed shelf of up to $125 millionSEC filing - marketscreener.com
Calcimedica Inc Files For Mixed Shelf Of Up To $125 MillionSEC Filing - TradingView
CalciMedica (NASDAQ: CALC) files shelf to offer up to $125M in securities - Stock Titan
CalciMedica (NASDAQ: CALC) outlines Auxora pipeline, halted AKI trial and going concern risk - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CALCForm 8-KCurrent report - ADVFN Ltd
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates - PR Newswire
Retail Trends: Whats next for CalciMedica Inc stock2025 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
CALC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CALC SEC FilingsCALCIMEDICA INC 10-K, 10-Q, 8-K Forms - Stock Titan
Jobs Data: Is Vistagen Therapeutics Inc. stock a top pick in earnings seasonGold Moves & Reliable Intraday Trade Alerts - baoquankhu1.vn
Does CalciMedica Inc. meet Warren Buffett’s criteria2025 Stock Rankings & Weekly High Conviction Ideas - mfd.ru
Should I set a stop loss on CalciMedica Inc.July 2025 Momentum & Weekly Watchlist for Consistent Profits - mfd.ru
Aug Highlights: What’s the fair value of DUK.PRA stockQuarterly Trade Review & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Earnings Risk: Does CalciMedica Inc meet Warren Buffetts criteria2025 Price Momentum & Technical Pattern Recognition Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
How Is The Market Feeling About CalciMedica Inc? - Benzinga
What is CalciMedica Inc.’s book value per shareWeekly Trend Summary & AI Enhanced Trading Signals - mfd.ru
CalciMedica downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
CalciMedica Shares Plunge After Discontinuing Phase II AKI Study - Citeline News & Insights
CalciMedica stock downgraded to Neutral by H.C. Wainwright after trial halt - Investing.com Canada
CalciMedica’s stock drops 75% on acute kidney injury trial termination - Clinical Trials Arena
CALC Stock Slumped 76% On Wednesday — Here’s Why - Asianet Newsable
CalciMedica discontinues AKI trial following safety concerns By Investing.com - Investing.com South Africa
CalciMedica discontinues Phase 2 KOURAGE trial following committee recommendation By Investing.com - Investing.com Nigeria
CalciMedica Discontinues Trial, Stock Faces Volatility - intellectia.ai
CalciMedica discontinues Phase 2 KOURAGE trial following committee recommendation - Investing.com
Calcimedica Discontinues Phase 2 Kourage Trial - TradingView
CalciMedica Ends KOURAGE Trial, Extends Cash Runway - TipRanks
Sector Update: Health Care - marketscreener.com
CalciMedica oversold on KOURAGE news, says Oppenheimer - TipRanks
CalciMedica ( CALC) Stock: Stops Phase 2 KOURAGE trial amid Enrollment Criteria Concerns - parameter.io
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Gold Jumps Over 4%; Seagate Shares Gain After Q2 Results - Benzinga
Calcimedica sags on halt of Auxora trial in acute kidney injury - bioworld.com
CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis - Benzinga
CalciMedica Shares Hit 52-Week Low After Ending Auxora Trial - marketscreener.com
Nasdaq Gains 150 Points; Starbucks Shares Rise After Strong Sales - Benzinga
CalciMedica stock craters as trial stopped over 'safety concern' - Fierce Biotech
CalciMedica tumbles as safety concerns halt trial of kidney injury drug - TradingView
CalciMedica stock plunges after discontinuing kidney injury trial By Investing.com - Investing.com Australia
CalciMedica stock plunges after discontinuing kidney injury trial - Investing.com
CalciMedica Halts Phase 2 KOURAGE Trial After Safety Review - TipRanks
CalciMedica discontinues AKI trial following safety concerns - Investing.com
CalciMedica announces discontinuation of Phase 2 KOURAGE clinical trial - TipRanks
CalciMedica Inc Discontinues Phase 2 KOURAGE Trial - TradingView
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation - PR Newswire
Does CalciMedica Inc have consistent dividend growthSell Signal & Real-Time Market Sentiment Reports - baoquankhu1.vn
Aug Catalysts: Why is Neurocrine Biosciences Inc stock going upPortfolio Update Report & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Why CalciMedica Is A Stock To Watch - Nasdaq
Will CalciMedica Inc benefit from rising consumer demandEarnings Summary Report & Fast Moving Market Watchlists - baoquankhu1.vn
CalciMedica (NASDAQ:CALC) Upgraded to Sell at Wall Street Zen - Defense World
One new option listing on January 13th - TipRanks
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):